ePrints

How to use mTOR inhibitors in children

Lookup NU author(s): Dr Yincent TseORCiD, Nicola Vasey, Dr Rhys ThomasORCiD, Dr Suzy Leech, Dr Stephen Owens, Professor John SayerORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© Author(s) (or their employer(s)) 2025.Paediatricians across many specialities and pharmacists are increasingly being asked to prescribe, or jointly look after, children treated with mammalian target of rapamycin (mTOR) inhibitors (eg, sirolimus and everolimus). There is an expanding list of conditions including tuberous sclerosis and vascular malformations where treatment with mTOR inhibitors may help. This brief practice pointer summarises the practical steps before starting these treatments, what potential side effects to discuss with families and what monitoring arrangements should be put in place.

Publication metadata

Author(s): Tse Y, Vasey N, Thomas R, Leech S, Owens S, Sayer J

Publication type: Article

Publication status: Published

Journal: Archives of Disease in Childhood: Education and Practice Edition

Year: 2025

Pages: epub ahead of print

Online publication date: 16/02/2025

Acceptance date: 31/01/2025

ISSN (print): 1743-0585

ISSN (electronic): 1743-0593

Publisher: BMJ Publishing Group

URL: https://doi.org/10.1136/archdischild-2024-327852

DOI: 10.1136/archdischild-2024-327852

Altmetrics

Share